| 1. |
The fixed-drug combination lopinavir/ritonavir [Kaletra; Abbott Laboratories] will be fully funded by Pharmac, New Zealand's drug subsidy agency, from 1 July 2004, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Improved labelling, education needed for safe OTC analgesic use |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Confidence in hepatitis B vaccine hit by thiomersal concerns |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Drug therapy + standard treatment adds value in prostate cancer? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 5-5
&NA;,
Preview
|
|
摘要:
Prostate cancer is a prevalent and costly disease in the US, and the most common cancer among men. Non-surgical therapy frequently consists of androgen deprivation therapy (ADT) or radiation treatment combined with hormonal therapy. A study conducted in the US and presented at the 9th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Arlington, Virginia, US; May 2004] revealed that the addition of hormonal therapy to a regimen of radiation treatment was cost effective in patients with locally-advanced prostate cancer.1A second US-based study presented at the conference contends that although the risk of osteoporotic fracture associated with ADT could be reduced by the addition of bisphosphonate therapy, the extra benefit may not be worth the additional cost.2
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Treatment of hypertensive crisis with sodium nitroprusside appears to be associated with similar patient outcomes to those of fenoldopam, but at significantly lower cost, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
CTL precursor-oriented peptide vaccination in colorectal cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
ITF 1697: potential to reduce infarct size? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Aspirin may prevent breast cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
HRT increases the risk of false positive recall after mammography, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Moxifloxacin: sequential therapy produces rapid improvements in CAP |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1440,
2004,
Page 11-12
RM Poole,
N Moreland,
Preview
|
|
摘要:
The broad spectrum antibacterial agent moxifloxacin [Avelox] has advantages over high-dose ceftriaxone with or without erythromycin in the treatment of community-acquired pneumonia (CAP), according to a study presented at the 14th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) [Prague, Czech Republic; May 2004]. In this study, which involved almost 400 patients, clinical success rates were comparable among moxifloxacin and ceftriaxone/erythromycin recipients. However, fever and chest pain resolved more rapidly among patients who received moxifloxacin. The benefits of sequential moxifloxacin therapy in CAP were confirmed in a post-marketing surveillance study also presented at the meeting. Clinical improvement was achieved within 3 days of the initiation of treatment in more than half of the patients, and 90% experienced improvements within 7 days.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
